ArticleArthritis & rheumatology (Hoboken, N.J.)2022

Additional points to consider before incorporating the Food and Drug Administration-approved therapies for systemic sclerosis-associated interstitial lung disease: comment on the article by Khanna et al.

Markus BredemeierPubMed ↗Publisher ↗

No numbers read from the abstract.